approval
saveVENCLEXTA (VENETOCLAX) — FDA approval
community read0 votes
Sponsor: ABBVIE. Form: TABLET. Route: ORAL
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- phase 1 2 completionAbbVie Inc — venetoclax (Phase I/II Trial Completion)Apr 30, 2026 · 155d ago
- phase 3 initiationInstitute of Hematology and Blood Diseases Hospital — venetoclax (Phase III Trial Initiation)Apr 29, 2026 · 156d ago
- approvalVENCLEXTA (VENETOCLAX) — FDA approvalFeb 19, 2026 · 225d ago
- approvalVENCLEXTA (VENETOCLAX) — FDA approvalJun 15, 2022 · 1570d ago
- approvalVENCLEXTA (VENETOCLAX) — FDA approvalOct 22, 2021 · 1806d ago
- approvalVENCLEXTA (VENETOCLAX) — FDA approvalOct 4, 2021 · 1824d ago
- approvalVENCLEXTA (VENETOCLAX) — FDA approvalNov 19, 2020 · 2143d ago
- approvalVENCLEXTA (VENETOCLAX) — FDA approvalOct 16, 2020 · 2177d ago
same company · ±60 days · 6
- approvalIMBRUVICA (IBRUTINIB) — FDA approvalDec 20, 2017
- approvaladalimumab: HUMIRA (ADALIMUMAB) — FDA approvalDec 14, 2017
- approvalCARIPRAZINE HYDROCHLORIDE: VRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approvalNov 9, 2017
- approvalCARIPRAZINE HYDROCHLORIDE: VRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approvalNov 9, 2017
- approvalIMBRUVICA (IBRUTINIB) — FDA approvalFeb 16, 2018
- approvalIMBRUVICA (IBRUTINIB) — FDA approvalFeb 16, 2018
🐶 often sniffed alongside
top 7- drugVENCLEXTA82 co-mentions · 22 sources
- tagApproval80 co-mentions · 20 sources
- tagSmall Molecule40 co-mentions · 20 sources
- tagOncology2 co-mentions · 2 sources
- tagHematology2 co-mentions · 1 sources
- companyInstitute of Hematology and Blood Diseases Hospital1 co-mentions · 1 sources
- tagAML1 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that